OPB-101

N/A

Report date: 2025/06/26 20:00:07

Base Information

Drug NameOPB-101

Drug Alias NameOPB-101

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsMesothelin modulators

TargetsMesothelin

Therapy Area/IndicationsOvarian DiseasesOvarian Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesOutpace Bio Inc

China Registration ClassN/A

Develop Information

Active CompaniesOutpace Bio Inc

Inactive CompaniesN/A

Active IndicationsOvarian DiseasesOvarian Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A